Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab added to concurrent chemoradiotherapy for locally advanced non-small cell lung cancer
NL-OMON21439Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Objective rate of local control. Started Feb 2008; status: recruiting.
02
Drugs
cetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON21439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21439.